1.Alexopoulos, GS, Katz, IR, Reynolds, CF III, et al.The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med. October 2001:1–86. Special Report.
2.Krishnan, KRR, Hays, JC, Tupler, LA, et al.Clinical and phenomenological comparisons of late-onset and early-onset depression. Am J Psychiatry. 1995;152:785–788.
3.Steffens, DC, Skoog, I, Norton, MC, et al.Prevalence of depression and its treatment in an elderly population: the Cache County Study. Arch Gen Psychiatry. 2000;57:601–607.
4.Luber, MP, Meyers, BS, Williams-Russo, PG, et al.Depression and service utilization in elderly primary care patients. Am J Geriatr Psychiatry. 2001;9:169–176.
5.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6.Lenze, EJ. Comorbidity of depression and anxiety in the elderly. Curr Psychiatry Rep. 2003;5:62–67.
7.Alexopoulos, GS, Borson, S, Cuthbert, BM, et al.Assessment of late life depression. Biol Psychiatry. 2002;52;164–174.
8.Conwell, Y, Duberstein, PR, Caine, ED. Risk factors for suicide in late life. Biol Psychiatry. 2002;52:193–204.
9.Hirschfeld, RMA, Russell, JM. Assessment and treatment of suicidal patients. N Eng J Med. 1997;337:910–915.
10.Szanto, K, Mulsant, BH, Houck, P, et al.Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry. 2003;60:610–617.
11.Krishnan, KRR. Biological risk factors in late depression. Biol Psychiatry. 2002;52:185–192.
12.Whyte, EM, Mulsant, BH. Post stroke depression: epidemiology, psychopathology, and biological treatment. Biol Psychiatry. 2002;52:253–264.
13.Devanand, DP. Comorbid psychiatric disorders in late life depression. Biol Psychiatry. 2002;52:236–242.
14.Krishnan, KR, Hays, JC, Blazer, DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497–501.
15.Robinson, RG, Schultz, SK, Castillo, C, et al.Nortriptyline versus fluoxetine in the treatment of depression and in short term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–359.
16.Alexopoulos, GS, Kiosses, DN, Choi, SJ, et al.Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry. 2002;159:1929–1932.
17.Miller, MD, Lenze, EJ, Dew, MA, et al.Effect of cerebrovascular risk factors in depression treatment outcome in later life. Am J Psychiatry. 2002;10:592–598.
18.Salloway, S, Boyle, PA, Correia, S, et al.The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed out-patients. Am J Psychiatry. 2002;10:107–111.
19.Bruce, ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry. 2002;52:175–184.
20.Arean, PA, Cook, BL. Psychotherapy and combined psychotherapy/pharmacology for late life depression. Biol Psychiatry. 2002;52:293–303.
21.Gallagher-Thompson, D, Hanley-Peterson, P, Thompson, LW. Maintenance of gains versus relapse following brief psychotherapy for depression. J Consult Clin Psychol. 1990;58:371–374.
22.Reynolds, CF III, Frank, E, Perel, JM, et al.Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39–45.
23.Lenze, EJ, Dew, MA, Mazumdar, S, et al.Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects of social adjustment. Am J Psychiatry. 2002;159:466–468.
24.Unützer, J, Katon, W, Callahan, CM, et al.Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836–2845.
25.Salzman, C, Wong, E, Wright, BC. Drug and ECT treatment of depression in the elderly, 1996-2001: a literature review. Biol Psychiatry. 2002;52:265–284.
26.Kirby, D, Harrigan, S, Ames, D. Hyponatremia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatric Psychiatry. 2002;17:231–237.
27.Heiligenstein, JH, Ware, JE, Buesterien, KM, et al.Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr. 1995;7(suppl):125–137.
28.Small, GW, Hamilton, SH, Bystritsky, A, et al.Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr. 1995;7(suppl):41–53.
29.Koran, LM, Hamilton, SH, Hertzman, M, et al.Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1995;15:421–427.
30.Arranz, FJ, Ros, S. Effects of comorbidity and polypharmacy in the clinical usefulness of sertraline in elderly depressed patients: an open multicenter study. J Affect Disor. 1997;46:285–291.
31.Schneider, LS, Nelson, JC, Clary, CM, et al.An 8-week multicenter, parallel group, double-blind, placebo-controlled study of sertraline in elderly patients with major depression. Am J Psychiatry. 2003;160:1277–1285.
32.Bump, GM, Mulsant, BH, Pollock, MG, et al.Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13:38–44.
33.Mulsant, BH, Pollock, BG, Nebes, RD, et al.A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6 week outcome. J Clin Psychiatry. 1999;60(suppl 20):16–20.
34.Dunner, DL, Cohn, JB, Walshe, T III, et al.Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992;53(suppl):57–60.
35.Reynolds, CF III. Paroxetine treatment of depression of late life. Psychopharm Bull. 2003;37(suppl):123–134.
36.Rapaport, MH, Schneider, LS, Dunner, DL, et al.Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64:1065–1074.
37.Karlsson, I, Godderis, K, De Mendonca, A, Lima, C. A randomized, double-blind comparison of the efficacy and safety of citalopram combined with mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Clin Psychiatry. 2000;15:295–305.
38.Kyle, CJ, Peterson, HEH, Overo, KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety. 1998;8:147–153.
39.Altamura, AC, Mauri, MC, Rudas, N, et al.Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(suppl 1):S25–S37.
40.Scher, M, Krieger, JN, Juergens, S. Trazodone and priapism. Am J Psychiatry. 1983;140:1362–1363.
41.Weihs, KL, Settle, EC Jr, Batey, SR, et al.Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000;61:196–202.
42.Steffens, DC, Doraiswamy, PM, McQuoid, DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry. 2001;16:862–865.
43. Wellbutrin (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2001.
44.Amore, M, Ricci, M, Zanardi, R, et al.Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord. 1997;46:293–296.
45.Dierick, M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry. 1996;8:169–178.
46.Khan, A, Rudolph, R, Baumel, B, et al.Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharm Bull. 1995;31:753–758.
47.Mahaptra, SN. A randomized, double-blind, parallel group comparison of venlafaxine and dothiepin in geriatric patients with major depression. IJPC. 1997;51:209–213.
48.Staab, JP, Evans, DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety. 2000;12(suppl 1):63–68.
49.Goldberg, RJ. Antidepressant use in the elderly: current status of nefazodone, venlafaxine, and moclobemide. Drugs Aging. 1997;11:119–131.
50.Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.
51.Keller, MB, McCullough, JP, Klein, DN, et al.A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. NEJM. 2000;342:1462–1470.
52.Dunner, DL, Laird, LK. Comparative safety and tolerability of nefazodone. J Clin Psychiatry. 2003;63(suppl 1):33–36.
53.Hoyberg, OJ, Maragakis, B, Mullin, J, et al.A double-blind multicenter comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93:184–190.
54.Schatzberg, AF, Kremer, C, Rodrigues, HE, et al.Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10:541–550.
55.Abrams, R. Electroconvulsive Therapy. 4th ed. New York, NY: Oxford Press; 2002.
56.Small, JG, Kellams, JJ, Milstein, , et al.Complications with electroconvulsive treatment combined with lithium. Biol Psychiatry. 1980;15:103–112.